CN100367981C - Medicine for treating cardio vascular disease - Google Patents
Medicine for treating cardio vascular disease Download PDFInfo
- Publication number
- CN100367981C CN100367981C CNB2005100428176A CN200510042817A CN100367981C CN 100367981 C CN100367981 C CN 100367981C CN B2005100428176 A CNB2005100428176 A CN B2005100428176A CN 200510042817 A CN200510042817 A CN 200510042817A CN 100367981 C CN100367981 C CN 100367981C
- Authority
- CN
- China
- Prior art keywords
- fructus hippophae
- treatment
- medicine
- hippophae flavone
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a novel medicine for treating cardiovascular diseases, which is prepared from hippophae rhamnoides flavone, red sage root, chuanxiong rhizome and talcum powder according to weight proportion. The present invention has unique formula and conspicuous curative effect and effectively prevents and treats cardiovascular diseases.
Description
Affiliated technical field: the present invention relates to a kind of treatment coronary heart disease, anginal medicine, specifically is exactly a kind of treatment coronary heart disease of the middle Tibetan medicine feedstock production of Qinghai-Tibet Platean, medicine of angina pectoris disease of utilizing.
Background technology: the Qinghai-Tibet Platean is owing to be located in the plateau, high height above sea level anoxia, coronary heart disease, angina pectoris disease and Cardiovascular system disorder become first of the five big diseases, the sickness rate fatality rate is more outstanding all interiorly, the middle Tibetan medicine resource of utilization Qinghai-Tibet Platean, the traditional drugs of development ethnic mimority area, utilize local resources, healthy cause service for this nationality, country even the people of the world, for making contributions and starting one's career the exploitation great Northwest, capture Cardiovascular system disorder, reduce incidence rate and fatality rate, the therapeutical effect of Tibetan medicine in excavation and the raising.
Summary of the invention: purpose of the present invention is to provide a kind of treatment coronary heart disease, anginal medicine exactly, and it can improve cardiac function, and allevating angina pectoris improves the painstaking effort rheology.
Technical scheme of the present invention is based on understanding and the Therapeutic Principle of Tibetanmedicine to cardiovascular disease mechanism, achieve with reference to modern study, treasure-house from motherland's medicine, choose the merit of the thrombolytic of promoting blood circulation, operation QI and blood, blood supply, air feed, the natural medicinal plants of microcirculation improvement, by the theory of Chinese medical science prescription, skim the cream off milk, bring into play the effect of its blood circulation promoting, ischemia resisting, anoxia alleviation cardiovascular pathological changes generation development.Concrete technical scheme of the present invention is that medicine of the present invention is made of following component: component is by weight:
Fructus Hippophae flavone 80-90, Radix Salviae Miltiorrhizae 3-8, Rhizoma Chuanxiong 2-4, Pulvis Talci 5-10
Preferred weight part proportioning of medicine of the present invention is:
Fructus Hippophae flavone 81-85, Radix Salviae Miltiorrhizae 3-7, Rhizoma Chuanxiong 2-4, Pulvis Talci 5-7
Optimum weight part proportioning of the present invention is:
Fructus Hippophae flavone 83.34, Radix Salviae Miltiorrhizae 6.66, Rhizoma Chuanxiong 3.34, Pulvis Talci 6.66
Feature of the present invention is also that described Fructus Hippophae flavone is meant and contains isorhamnetin C
18H
12O
7Fructus Hippophae flavone between 1/150-1/30.
Feature of the present invention is also that in addition described Fructus Hippophae flavone is meant that isorhamnetin is C
18H
12O
7The Fructus Hippophae flavone of content between 2/75-1/30.
The present invention is owing to adopt such scheme, and show that through clinical use following advantage is arranged: (1) has arrhythmia, myocardial ischemia and allevating angina pectoris effect; (2) reactive oxygen free radical there is scavenging action, but delaying human body caducity; (3) can increase immune function of human body; (4) coronary blood flow increasing and myocardial flow obviously reduce myocardial oxygen consumption; (5) energy anti peroxidation of lipid, antagonism GSH exhausts hepatic injury being had the certain protection effect, and can protect the lipid within endothelial cells amount of peroxides, alleviates the damage of cell membrane; (6) to anticancer certain effect arranged.The present invention also can make said dosage form on the pharmaceutics as required.
Be the therapeutic effect of explanation the present invention to the cardiovascular diseases, the present invention is through system's clinical observation case study totally 418 examples, and the treatment group is 312 examples, its male's 186 examples, and women's 126 examples, 59.4 years old mean age, the course of treatment is the longest 25 years, and is the shortest 2 months, average 5.22 years.Treatment coronary heart disease, the heart twist disease effective percentage 62.2%.
The total effects that the present invention treats coronary heart disease and matched group compares (table 1)
| The group example | The example number | Produce effects | Progressive | Invalid | Total effective rate (%) |
| The treatment group | 312 | 148 | 143 | 23 | 92.5 |
| Matched group | 106 | 36 | 52 | 18 | 83.0 |
(P＜0.05)
The present invention compares (table 2) to two groups of Electrocardiographic curative effects of patient
| The group example | The example number | Produce effects | Improve | Invalid | Increase the weight of | Total effective rate (%) |
| The treatment group | 283 | 68 | 108 | 102 | 5 | 62.2 |
| Matched group | 91 | 14 | 32 | 41 | 4 | 50.5 |
The present invention compares (table 3) to the curative effect of two groups of treatment thoracic obstruction patient cardinal symptoms
| Symptom | Group | The example number | Produce effects | Progressive | Invalid | Total effective rate (%) |
| Uncomfortable in chest | Treatment group matched group | 308 103 | 156 38 | 134 48 | 18 17 | 94.2 83.5 |
| Weak | Treatment group matched group | 288 77 | 122 22 | 152 40 | 34 15 | 88.2 80.5 |
| Breathe hard | Treatment group matched group | 296 89 | 130 30 | 136 41 | 30 18 | 89.9 79.8 |
| Cardiopalmus | Treatment group matched group | 294 87 | 134 25 | 134 46 | 26 16 | 91.2 81.6 |
| Pained | Treatment group matched group | 301 101 | 152 34 | 128 50 | 21 17 | 93.0 83.2 |
| Nervous | Treatment group matched group | 23 66 | 101 20 | 118 34 | 19 12 | 92.0 81.8 |
The present invention twists disease curative effect relatively (table 4) to two groups of patients' the heart
| Classification | The example number | Produce effects | Improve | Invalid | Total effective rate (%) | |
| Slightly | Treatment group matched group | 90 35 | 33 12 | 52 19 | 5 4 | 94 88.6 |
| Moderate | Treatment group matched group | 199 63 | 72 19 | 118 33 | 18 11 | 90.9 82.5 |
| Severe | Treatment group matched group | 13 4 | 3 1 | 7 2 | 3 1 | 75 75.0 |
The present invention is to hemorheological influence (table 5)
The comparison of two groups of patient treatment front and back hemorheology index variations (X ± SD)
| The treatment group | Matched group | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Blood viscosity (V) | 4.66±0.88 | 3.58±0.65* | 4.64±1.01 | 3.85±0.78 |
| Reduced blood fluid viscosity (OV) | 4.42±0.87 | 3.32±0.66* | 4.72±0.99 | 3.65±0.95 |
| All resistances (RT) | 1780.0± 412.3 | 1176.6± 776.3* | 1738.9± 368.7 | 1298.6± 886.5 |
Annotate: compare * P＜0.05 before and after the treatment.
The present invention is to hemodynamic influence (table 6)
Hemodynamic comparison before and after two groups of patient treatments
| The treatment group | Matched group | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| SV | 61.3±14.2 | 70.5±15.4* | 60.2±16.3 | 65.7±17.5 |
| CO | 4.4±1.3 | 5.6±1.1* | 4.2±1.4 | 5.0±1.1 |
Specific embodiment:
Embodiment 1: take by weighing raw material (kilogram) by following proportioning
The Fructus Hippophae flavone 80 that contains isorhamnetin 2/75, Radix Salviae Miltiorrhizae 7, Rhizoma Chuanxiong 4, Pulvis Talci 9.
Embodiment 2: take by weighing raw material (kilogram) by following proportioning
The Fructus Hippophae flavone 85 that contains isorhamnetin 1/35, Radix Salviae Miltiorrhizae 6, Rhizoma Chuanxiong 3.5, Pulvis Talci 5.5.
Embodiment 3: take by weighing raw material (kilogram) by following proportioning
The Fructus Hippophae flavone 83.34 that contains isorhamnetin 1/30, Radix Salviae Miltiorrhizae 6.66, Rhizoma Chuanxiong 3.34, Pulvis Talci 6.66.
Embodiment 4: take by weighing raw material (kilogram) by following proportioning
Fructus Hippophae flavone 89, Radix Salviae Miltiorrhizae 3, Rhizoma Chuanxiong 3, Pulvis Talci 5.
Claims (5)
1. treat coronary heart disease, anginal medicine for one kind, it is characterized in that the medicament that it is made by the following weight proportion raw material:
Fructus Hippophae flavone 80-90, Radix Salviae Miltiorrhizae 3-8, Rhizoma Chuanxiong 2-4, Pulvis Talci 5-10.
2. treatment coronary heart disease according to claim 1, anginal medicine is characterized in that it is formed by following raw material weight proportioning:
Fructus Hippophae flavone 81-85, Radix Salviae Miltiorrhizae 3-7, Rhizoma Chuanxiong 2-4, Pulvis Talci 5-7.
3. treatment coronary heart disease according to claim 1, anginal medicine is characterized in that the weight proportion of each raw material is:
Fructus Hippophae flavone 83.34, Radix Salviae Miltiorrhizae 6.66, Rhizoma Chuanxiong 3.34, Pulvis Talci 6.66.
4. according to claim 1 or 2 or 3 described a kind of treatment coronary heart disease, anginal medicine, it is characterized in that described Fructus Hippophae flavone is meant and contain isorhamnetin C
18H
12O
7Fructus Hippophae flavone between 1/150 ~ 1/30.
5. according to claim 1 or 2 or 3 described a kind of treatment coronary heart disease, anginal medicine, it is characterized in that said Fructus Hippophae flavone is meant the Fructus Hippophae flavone of isorhamnetin content in the 2/75-1/30 scope.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100428176A CN100367981C (en) | 2005-06-15 | 2005-06-15 | Medicine for treating cardio vascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100428176A CN100367981C (en) | 2005-06-15 | 2005-06-15 | Medicine for treating cardio vascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709386A CN1709386A (en) | 2005-12-21 |
| CN100367981C true CN100367981C (en) | 2008-02-13 |
Family
ID=35705718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100428176A Expired - Fee Related CN100367981C (en) | 2005-06-15 | 2005-06-15 | Medicine for treating cardio vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100367981C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078377A (en) * | 2011-01-13 | 2011-06-01 | 铁顺良 | Medicament for treating cardio-cerebrovascular disease and gastropathy |
| CN103520272B (en) * | 2013-09-18 | 2015-07-01 | 铁顺良 | Drug for treating coronary disease and stenocardia |
| CN103800635A (en) * | 2014-03-12 | 2014-05-21 | 邹琳 | Medicinal and edible two-purpose composition for preventing and treating coronary heart disease and preparation method thereof |
| CN115778999A (en) * | 2022-12-01 | 2023-03-14 | 山东中健康桥制药有限公司 | A Chinese medicinal composition for treating coronary heart disease and angina pectoris, and its preparation method |
| CN116942728A (en) * | 2023-06-20 | 2023-10-27 | 刘宗杰 | Traditional Chinese medicine composition for treating cardiovascular metabolic diseases and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113781A (en) * | 1994-06-16 | 1995-12-27 | 傅正和 | Viscosity-reducing and antithrombotic tablet and its producing technology |
-
2005
- 2005-06-15 CN CNB2005100428176A patent/CN100367981C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113781A (en) * | 1994-06-16 | 1995-12-27 | 傅正和 | Viscosity-reducing and antithrombotic tablet and its producing technology |
Non-Patent Citations (1)
| Title |
|---|
| 沙棘心血康口服液对高血脂动物血脂的影响. 何志茂，马欣.陕西中医学院学报，第22卷第6期. 1999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1709386A (en) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN102078510B (en) | Chinese medicinal composition for treating coronary heart disease | |
| CN101332246B (en) | Traditional Chinese medicine preparation for treating coronary heart disease and angina | |
| CN100367981C (en) | Medicine for treating cardio vascular disease | |
| CN101433689A (en) | Kudzu root and longstamen onion bulb oral liquid and preparation method | |
| CN100542579C (en) | A kind of heart tonifying capsule for the treatment of coronary heart disease | |
| CN102526276A (en) | Anti-hypertension medicinal composition and preparation method for same | |
| CN101129464A (en) | Traditional Chinese medicine composition for qi-benefitting blood circulation promoting and eliminating stasis activating meridian and processes for producing same | |
| CN103239562B (en) | Traditional Kazak medicament composition for treating diabetes mellitus and preparation method of traditional Kazak medicament composition | |
| CN102614474A (en) | Traditional Chinese medicine for treating coronary heart disease and preparation method thereof | |
| CN102048939B (en) | Medicament for treating sinus bradycardia | |
| CN104906274A (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN103520272B (en) | Drug for treating coronary disease and stenocardia | |
| CN101897753B (en) | Traditional Chinese medicine for treating coronary disease and preparation method thereof | |
| CN100382834C (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN1730093A (en) | Chinese traditional medicine preparation for treating cancer and application thereof | |
| CN101703736A (en) | Chinese medicament for treating coronary disease | |
| CN100558387C (en) | The Chinese medicinal capsule of treatment heart failure | |
| CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
| CN103919852A (en) | Blending method of heart-protecting pill mixed powder containing musk for preventing and treating chronic cardiac insufficiency and heart failure | |
| CN1331505C (en) | Mightiness pulse invigorating capsule and its preparation method | |
| CN104056200B (en) | Oral traditional Chinese medicine combination for treating lumbar spinal stenosis | |
| CN103127413B (en) | Pharmaceutical preparation for treating coronary diseases | |
| CN102526614A (en) | Chinese medicinal kidney healing powder for treating chronic renal failure | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |